2. Шелыгин Ю.А., Ивашкин В.Т., Ачкасов С.И. с соавт. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023; 22(3): 10–49. [Shelygin Yu.A., Ivashkin V.T., Achkasov S.I. et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologiya = 2023; 22(3): 10–49 (In Russ.)]. https://dx.doi.org/10.33878/2073-7556-2023-22-3-10-49. EDN: CQJBNA.

3. Bernstein C.N., Blanchard J.F., Leslie W. et al. The incidence of fracture among patients with inflammatory bowel disease.A population-based cohort study. Ann Intern Med. 2000; 133(10): 795–99.https://dx.doi.org/10.7326/0003-4819-133-10-200011210-00012.

4. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В. с соавт. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021; 24(2): 4–47. [Belaya Z.E., Belova K.Yu., Biryukova E.V. et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2021; 24(2): 4–47 (In Russ.)]. https://dx.doi.org/10.14341/osteo12930. EDN: TUONYE.

5. Camacho P.M., Petak S.M., Binkley N. et al. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2016. Endocr Pract. (2016; 22(Suppl 4): 1–42. https://dx.doi.org/10.4158/EP161435.GL.

6. Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y.; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30(1): 3–44. https://dx.doi.org/10.1007/s00198-018-4704-5.

7. Смирнов И.Е., Рошаль Л.М., Кучеренко А.Г. с соавт. Изменения содержания костных биомаркеров и цитокинов в сыворотке крови при сочетанной травме у детей. Российский педиатрический журнал. 2017; 20(6): 371–378. [Smirnov I.E., Roshal L.M., Kucherenko A.G. et al. Changes in the blood serum content of bone biomarkers and cytokines in children with combined trauma. Rossiyskiy pediatricheskiy zhurnal = Russian Journal of Pediatrics. 2017; 20(6): 371–378 (In Russ.)].https://dx.doi.org/10.18821/1560-9561-2017-20-6-371-378. EDN: YPKFUY.

8. Герштейн Е.С., Тимофеев Ю.С., Зуев А.А., Кушлинский Н.Е. Лиганд-рецепторная система RANK/RANKL/OPG и ее роль при первичных новообразованиях костей (анализ литературы и собственные результаты). Успехи молекулярной онкологии. 2015; 2(3): 51–59. [Gershtein E.S., Timofeev Yu.S., Zuev A.A., Kushlinskii N.E. Ligand-receptor system RANK/RANKL/OPG and its role in primary bone tumors (literature analysis and own results). Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology. 2015; 2(3): 51–59 (In Russ.)]. https://dx.doi.org/10.17650/2313-805X-2015-2-3-51-59. EDN: VHUMUJ.

9. Аганов Д.С., Тыренко В.В., Цыган Е.Н. с соавт. Роль цитокиновой системы RANKL/RANK/OPG в регуляции минерального обмена костной ткани. Гены и клетки. 2014; 9(4): 50–52. [Aganov D.S., Tyrenko V.V., Tsygan E.N. et al. The role of cytokine system RANKL/RANK/OPG in the regulation of bone metabolism. Geny i kletki = Genes and Cells. 2014; 9(4): 50–52 (In Russ.)]. EDN: YRWLDR.

10. Майлян Э.А. Мультифакторность этиопатогенеза остеопороза и роль генов канонического Wnt-сигнального пути. Остеопороз и остеопатии. 2015; 18(2): 15–19. [Mailyan E.A. Multifactorial pathogenesis of osteoporosis and the role of genes of canonical wnt-signaling pathway. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2015; 18(2): 15–19 (In Russ.)]. EDN: WDKOJB.

11. Mbalaviele G., Sheikh S., Stains J.P. et al. Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 2005; 94(2): 403–18. https://dx.doi.org/10.1002/jcb.20253.

12. Ali T., Lam D., Bronze M.S., Humphrey M.B. Osteoporosis in inflammatory bowel disease. Am J Med. 2009; 122(7): 599–604.https://dx.doi.org/10.1016/j.amjmed.2009.01.022.

13. Bernstein C.N., Blanchard J.F., Leslie W. et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000; 133(10): 795–99.https://dx.doi.org/10.7326/0003-4819-133-10-200011210-00012.

14. Shirazi K.M., Somi M.H., Rezaeifar P. et al. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2012; 18(4): 241–47. https://dx.doi.org/10.4103/1319-3767.98428.

15. Romas E. Clinical applications of RANK-ligand inhibition. Intern Med J. 2009; 39(2): 110–16.https://dx.doi.org/10.1111/j.1445-5994.2008.01732.x

16. Krela-Kazmierczak I., Szymczak-Tomczak A., Lykowska-Szuber L. et al. Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases. Adv Clin Exp Med. 2018; 27(4): 449–53. https://dx.doi.org/10.17219/acem/75675.

17. Turk N., Cukovic-Cavka S., Korsic M. et al. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2009; 21(2): 159–66. https://dx.doi.org/10.1097/MEG.0b013e3283200032.

18. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996; 239(2): 131–37. https://dx.doi.org/10.1046/j.1365-2796.1996.420765000.x.

19. Габрусская Т.В., Ревнова М.О., Кузьмина Д.А., Костик М.М. Оценка состояния костной минерализации и костного метаболизма у детей с воспалительными заболеваниями кишечника. Экспериментальная и клиническая гастроэнтерология. 2017; (7): 71–81. [Gabrusskaya T.V., Revnova M.O., Kuzmina D.A., Kostik M.M. Assessment of bone mineralization and bone metabolism in children with inflammatory bowel disease. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2017; (7): 71–81 (In Russ.)]. EDN: ZRPJTJ.

20. Jahnsen J., Falch J.A., Aadland E., Mowinckel P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: A population based study. Gut. 1997; 40(3): 313–19. https://dx.doi.org/10.1136/gut.40.3.313.

21. Tsai M.S., Lin C L., Tu Y.K. et al. Risks and predictors of osteoporosis in patients with inflammatory bowel diseases in an Asian population: A nationwide population-based cohort study. Int J Clin Pract. 2015; 69(2): 235–41. https://dx.doi.org/10.1111/ijcp.12526.

22. Moschen A.R., Kaser A., Enrich B. et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005; 54(4): 479–87. https://dx.doi.org/10.1136/gut.2004.044370.

23. Головач И.Ю. Нарушения минеральной плотности костной ткани и вторичный остеопороз при патологии гепатобилиарной системы и желудочно-кишечного тракта: на перекрестке проблем. Боль. Суставы. Позвоночник. 2012; (3): 49–60. [Golovach I.Yu. Disorders of bone mineral density and secondary osteoporosis in pathology of hepatobiliary system and gastrointestinal tract: At the crossing of problems. Bol’. Sustavy. Pozvonochnik = Pain. Joints. Spine. 2012; (3): 49–60 (In Russ.)]. EDN: QZVSOZ.

24. Иськова И. А. Остеопороз при хронических воспалительных заболеваниях кишечника и целиакии. Крымский терапевтический журнал. 2012; (2): 34–37. [Iskova I.O. Osteoporosis in chronic inflammatory bowel disease and celiac disease. Krymskiy terapevticheskiy zhurnal = Crimean Therapeutic Journal. 2012; (2): 34–37 (In Russ.)]. EDN: RTVNOF.

25. Ardizzone S., Bollani S., Bettica P. et al. Altered bone metabolism in inflammatory bowel disease: There is a difference between Crohn’s disease and ulcerative colitis. J Intern Med. 2000; 247(1): 63–70. https://dx.doi.org/10.1046/j.1365-2796.2000.00582.x.

26. Andreassen H., Hylander E., Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn’s disease: A case-control cross-sectional study of 113 patients. Am J Gastroenterol. 1999; 94(3): 824–28.https://dx.doi.org/10.1111/j.1572-0241.1999.00866.x.

27. Lima C.A., Lyra A. C., Rocha R., Santana G.O. Risk factors for osteoporosis in inflammatory bowel disease patients. World J Gastrointest Pathophysiol. 2015; 6(4): 210–18. https://dx.doi.org/10.4291/wjgp.v6.i4.210.

28. Gomes Coqueiro F., Rocha R., Menezes C.A. et al. What nutritional factors influence bone mineral density in Crohn’s disease patients? Intest Res. 2018; 16(3): 436–44. https://dx.doi.org/10.5217/ir.2018.16.3.436.

29. Steell L., Gray S.R., Russell R.K. et al. Pathogenesis of musculoskeletal deficits in children and adults with inflammatory bowel disease. Nutrients. 2021; 13(8): 2899. https://dx.doi.org/10.3390/nu13082899.

30. Луценко А.С., Рожинская Л.Я., Торопцова Н.В., Белая Ж.Е. Роль и место препаратов кальция и витамина D для профилактики и лечения остеопороза. Остеопороз и остеопатии. 2017; 20(2): 69–75. [Lutsenko A.S., Rozhinskaya L.Ya., Toroptsova N.V., Belaya Zh.E. The role of calcium and vitamin D medications in prevention and treatment of osteoporosis. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2017; 20(2): 69–75 (In Russ.)]. https://dx.doi.org/10.14341/osteo2017269-75. EDN: YOEIUQ.

31. Silvennoinen J., Lamberg-Allardt C., Karkkainen M. et al. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996; 240(5): 285–92. https://dx.doi.org/10.1046/j.1365-2796.1996.25862000.x.

32. Шварц Г.Я. Витамин D и D-гормон. М.: Анахарсис. 2005; 152 с. [Schwartz G.Ya. Vitamin D and D-hormone. Moscow: Anacharsis. 2005; 152 pp. (In Russ.)]. ISBN: 5-901352-56-4.

33. Беневоленская Л.И. Проблема остеопороза в современной медицине. Научно-практическая ревматология. 2005; 43(1): 4–7. [Benevolenskaya L.I. Osteoporosis problem in the modern medicine. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2005; 43(1): 4–7 (In Russ.)]. EDN: QBPIFT.

34. Дедов И.И., Рожинская Л.Я., Марова Е.И. Первичный и вторичный остеопороз: патогенез, диагностика, принципы профилактики и лечения. Методические пособия для врачей, 2 изд. М. 2003. [Dedov I.I., Rozhinskaya L.Ya., Marova E.I. Primary and secondary osteoporosis: pathogenesis, diagnosis, principles of prevention and treatment. Methodological manuals for doctors, 2nd ed. Moscow. 2003 (In Russ.)].

35. Бикбавова Г.Р., Ливзан М.А., Лопатина О.Е. Влияние дефицита микронутриентов и пищевых привычек на иммунный ответ и кишечный микробиоценоз у больных воспалительными заболеваниями кишечника: обзор. Фарматека. 2019; 26(2): 25–30. [Bikbavova G.R., Livzan M.A., Lopatina O.E. Effect of micronutrient deficiency and dietary habits on the immune response and intestinal microbiocenosis in patients with inflammatory bowel diseases: A review. Farmateka. 2019; 26(2): 25–30 (In Russ.)].https://dx.doi.org/10.18565/pharmateca.2019.2.25-30. EDN: YZCLLF.

36. Садовникова И.В., Мелкумова М.А. Дефицит витамина Д как фактор риска нарушений минерального обмена при коморбидных состояниях у детей, больных воспалительными заболеваниями кишечника. Медицина: теория и практика. 2019; 4(1): 84–91. [Sadovnikova I.V., Melkumova M.A. A deficiency of vitamin D as a risk factor for disorders of mineral metabolism in comorbid conditions in children with inflammatory bowel disease. Meditsina: teoriya i praktika = Medicine: Theory and Practice. 2019; 4(1): 84–91 (In Russ.)]. EDN: QTWPSU.

37. Bastos C.M., Araujo I.M., Nogueira-Barbosa M.H. et al. Reduced bone mass and preserved marrow adipose tissue in patients with inflammatory bowel diseases in long-term remission. Osteoporos Int. 2017; 28(7): 2167–76.https://dx.doi.org/10.1007/s00198-017-4014-3.

38. McCarthy D., Duggan P., O’Brien M. et al. Seasonality of vitamin D status and bone turnover in patients with Crohn’s disease. Aliment Pharmacol Ther. 2005; 21(9): 1073–83. https://dx.doi.org/10.1111/j.1365-2036.2005.02446.x.

39. De Laet C., Kanis J.A., Oden A. et al. Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporos Int. 2005; 16(11): 1330–38. https://dx.doi.org/10.1007/s00198-005-1863-y.

40. Azzopardi N., Ellul P. Risk factors for osteoporosis in Crohn’s disease: Infliximab, corticosteroids, body mass index, and age of onset. Inflamm Bowel Dis. 2013; 19(6): 1173–78. https://dx.doi.org/10.1097/MIB.0b013e31828075a7.

41. Noble C.L., McCullough J., Ho W. et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 27(7): 588–96. https://dx.doi.org/10.1111/j.1365-2036.2008.03599.x.

42. Habtezion A., Silverberg M.S., Parkes R. et al. Risk factors for low bone density in Crohn’s disease. Inflamm Bowel Dis. 2002; 8(2): 87–92. https://dx.doi.org/10.1097/00054725-200203000-00003.

43. Leslie W.D., Miller N., Rogala L., Bernstein C.N. Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD Cohort Study. Inflamm Bowel Dis. 2009; 15(1): 39–46. https://dx.doi.org/10.1002/ibd.20541.

44. Cawsey S., Padwal R., Sharma A. M. et al. Women with severe obesity and relatively low bone mineral density have increased fracture risk. Osteoporos Int. 2015; 26(1): 103–11. https://dx.doi.org/10.1007/s00198-014-2833-z.

45. Mauro M., Armstrong D. Evaluation of densitometric bone-muscle relationships in Crohn’s disease. Bone. 2007; 40(6): 1610–14. https://dx.doi.org/10.1016/j.bone.2007.02.026.

46. Lee N., Radford-Smith G.L., Forwood M. et al. Body composition and muscle strength as predictors of bone mineral density in Crohn’s disease. J Bone Miner Metab. 2009; 27(4): 456–63. https://dx.doi.org/10.1007/s00774-009-0059-5.

47. Лоренс Риггз Б., Мелтон Дж. Остеопороз. Этиология, диагностика, лечение. Пер. с англ. под общ. ред. Е.А. Лепарского. СПб.: БИНОМ: Невский диалект. 2000; 560 с. [Lawrence Riggs B., Melton J. Osteoporosis. Etiology, diagnosis, treatment. Translation from English under the general editorship of E.A. Leparsky. Saint Petersburg: BINOM: Nevsky dialect. 2000; 560 pp. (In Russ.)]. ISBN: 5-7989-0185-8.

48. Баранова И.К. Глюкокортикоид-индуцированный остеопороз – современное лечение и профилактика. Медицинский совет. 2008; (5–6): 48–56. [Baranova I.K. Glucocorticoid-induced osteoporosis – modern treatment and prevention. Meditsinskiy sovet = Medical Council. 2008; (5–6): 48–56 (In Russ.)]. EDN: MLISRX.

49. Rubin M.R., Bilezikian, J.P. Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab. 2002; 87(9): 4033–41.https://dx.doi.org/10.1210/jc.2002-012101.

50. Kawai V.K., Stein C.M., Perrien D.S., Griffin M.R. Effects of anti-tumor necrosis factor α agents on bone. Curr Opin Rheumatol. 2012; 24(5): 576–85. https://dx.doi.org/10.1097/BOR.0b013e328356d212.

51. Abreu M.T., Geller J.L., Vasiliauskas E.A. et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006; 40(1): 55–63. https://dx.doi.org/10.1097/01.mcg.0000190762.80615.d4.

52. Miheller P., Muzes G., Racz K. et al. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13(11): 1379–84. https://dx.doi.org/10.1002/ibd.20234.

53. Franchimont N., Putzeys V., Collette J. et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2004; 20(6): 607–14. https://dx.doi.org/10.1111/j.1365-2036.2004.02152.x.

54. Mauro M., Radovic V., Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn’s disease patients. Can J Gastroenterol. 2007; 21(10): 637–42. https://dx.doi.org/10.1155/2007/216162.

55. Colombel J.F., Sandborn W.J., Reinisch W. et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010; 362(15): 1383–95. https://dx.doi.org/10.1056/NEJMoa0904492.

56. Baban Y.N., Edicheria C.M., Joseph J. et al. Osteoporosis complications in Crohn’s disease patients: Factors, pathogenesis, and treatment outlines. Cureus. 2021; 13(12): e20564. https://dx.doi.org/10.7759/cureus.20564.